AcouSort
AcouSort is a Swedish medical technology company that develops acoustofluidic sample-preparation systems and OEM components for life science instrumentation. Its products are used to automate the handling, separation, washing, trapping, and preparation of biological samples in diagnostics, cell therapy, and laboratory workflows.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueAcoustofluidic modules and components embedded into third-party diagnostic and therapeutic instruments.
Benchtop AcouWash and AcouTrap systems used for evaluation, development, and workflow validation.
Technology licensing and related rights tied to use of AcouSort's platform.
Sales of systems, kits, and technical services supporting customer integration projects.
Customers
AcouSort sells primarily to life science instrument manufacturers that want to embed automated sample-preparation steps into diagnostic, analytics, and cell-therapy systems. It also works with universities, research institutions, and industrial partners that use AcouWash and AcouTrap for feasibility studies, workflow development, and scientific validation.
Buy OEM components and integration support to embed automated sample processing into instruments.
Use the technology to automate cell washing, separation, and handling in manufacturing workflows.
Evaluate AcouSort's platform for blood, plasma, and cell-processing steps in diagnostic systems.
Buy benchtop systems and evaluation kits for scientific studies and workflow validation.
Explore particle-removal and process-integration use cases in production workflows.
Strategy
AcouSort's strategy is to convert its acoustofluidics platform from technology validation into broader OEM adoption and recurring commercial use. The company focuses on partnerships with instrument makers, cell-therapy developers, and research institutions to prove integration, build scientific credibility, and create pathways to long-term agreements.
Embedded components can create repeatable revenue and deeper customer integration.
Pilot projects are the main route to scaled adoption in regulated life science workflows.
Multiple end markets reduce dependence on any single workflow or customer type.
Publications and conference exposure help de-risk adoption for OEM and research buyers.
Geography
AcouSort is headquartered in Sweden and serves customers across North America, Europe, and selected markets in Asia. The company also operates a U.S. subsidiary, AcouSort Inc., to support marketing and sales in North America, while its systems and partnerships are used internationally across research and commercial settings.
Risks
AcouSort is exposed to commercialization risk because its business depends on converting technical validation into customer adoption and OEM agreements. It also faces liquidity, technology, regulatory, and competition risks typical of early-stage medtech and life science tools companies, where development cycles are long and outcomes are uncertain.
- Liquidity riskImpact: HighLikelihood: High
The company relies on ongoing sales, grants, and funding to support operations before scale is reached.
Exposure - Commercialization riskImpact: HighLikelihood: High
Revenue depends on turning pilots and evaluations into OEM contracts and repeat orders.
Exposure - Technology development riskImpact: MediumLikelihood: Medium
The platform must continue to perform reliably across different biological workflows and customer systems.
Exposure - Competition riskImpact: MediumLikelihood: Medium
Customers can choose alternative sample-preparation technologies or in-house solutions.
Exposure: OEM and research markets.
- Regulatory and quality riskImpact: MediumLikelihood: Medium
Medical and life science customers require validated processes and quality systems.
Exposure: Medical device and cell therapy applications.
Accounting
Judgemental itemsProduct sales, license fees, services, and project work may be recognized differently and at different times.
Impact: Can shift revenue between quarters and affect comparability.
EU and other public contributions support innovation projects and may be recognized when conditions are met.
Impact: Can materially affect other income and R&D funding visibility.
Internally generated intangible assets and patent application fees are capitalized under the company's policy.
Impact: Affects asset values, amortization, and reported earnings.
Laboratory and office premises are leased, creating recurring lease expense.
Impact: Affects operating costs and fixed commitments.
Management must estimate future cash needs, backlog conversion, and project timing.
Impact: Can influence going-concern assessment and expense accruals.
Similar listed companies
Publicly listed companies with a comparable business focus.
Akso Health Group
AHG · Services-Business Services, NEC
Akso Health Group is a U.S.-incorporated holding company with operating subsidiaries in the United States and China that sell medical devices and offer healthcare-related services.
Cytosorbents Corp
CTSO · Surgical & Medical Instruments & Apparatus
Cytosorbents Corp develops blood purification and adsorption devices used in critical care, cardiac surgery, and other acute care settings.
Avantor, Inc.
AVTR · Laboratory Analytical Instruments
Accustem Sciences Inc.
ACUT · Pharmaceutical Preparations
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Last updated: 24/09/2026